Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in pediatric oncology patients with febrile neutropenia
2016-000466-33Phase 4Terminated
- Sponsor
- Aarhus University Hospital
- Start
- Mar 2016
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of piperacillin + tazobactam in febrile neutropenia (FN), sponsored by Aarhus University Hospital. Primary endpoints: Target attainment above MIC during dosing interval and Optimization of Tazocin treatment. Started Mar 2016; status: terminated.
02
Drugs
piperacillin + tazobactam
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on 2016-000466-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000466-33.